uÀÐ‰îAƒXƒ^ƒbƒtÐ‰îAŒ¤‹†A‹ÆÑ“™A‡“V“°‘åŠw‘åŠw‰@ ŽY•wl‰ÈŠw‚ÉŠÖ‚·‚é—lX‚ȏî•ñ‚ð‚²ˆÄ“à‚µ‚Ü‚·B

‡“V“°‘åŠw‘åŠw‰@@ŠeŒ¤‹†•ª–ìÐ‰î@l‘̂̐¶–½‹@”\

‹ÆÑ

¡‹ÆÑ

¡‹ÆÑi˜_•¶j2015”N
Œ¤‹†”ï | ‰p•¶Œ´’˜ | ‰p•¶‘à | ˜a•¶Œ´’˜ | ‰p•¶•ñ | ˜a•¶•ñ | ˜a•¶‘à | ˜a•¶’˜‘ |
µ‘ҍu‰‰i‘Ûj | µ‘ҍu‰‰i‘“àj‚»‚Ì‘¼iL•ñŠˆ“®‚ðŠÜ‚ށj |
Œ¤‹†”ï
  1. Œ¤‹†‘ã•\ŽÒF‰¡ŽR ˜amAŒ¤‹†•ª’SŽÒF’|“c@ÈA´…@r–¾Aç—t@•SŽqAƒ‚[ƒZƒ“@ƒ”ƒB[ƒWƒFA¼‰ª@ÎŽqA–k‘º@•¶•FA×ì@‚Ü‚äŽqA¼ì@ŠxD•½¬27”N“x(2015”N“x) Šî”ÕŒ¤‹†i‚ajiŠCŠOŠwp’²¸jŒ¤‹†Œv‰æ’²‘@ŠJ”­“rã‘‚É‚¨‚¯‚éŠÂ‹«‰˜õ‚̏¬Ž™Œ’N‰e‹¿‚ÉŠÖ‚·‚鍑Û‹¤“¯Œ¤‹†
  2. ’|“c@ÈA–q–ì^‘¾˜YD•½¬2‚V”N“x“ú•ê‚¨‚¬‚á[Œ£‹àŠî‹à100–œ‰~@V¶Ž™’áŽ_‘f«‹•ŒŒ«”]Ç‚É‚¨‚¯‚écaspase-6‚̐V‚½‚È–ðŠ„‚É‚Â‚¢‚Ä
  3. ¼‘º@—DŽqAŒ¤‹†•ª’SŽÒFÜ–΁@²AŽ›”ö@‘׋vA”ó–ì@‹»•vD•½¬27”N“x@Šw’·“Á•Ê‹¤“¯ƒvƒƒWƒFƒNƒgŒ¤‹†@Šà“àüˆÛ‰è×–E‚É‚æ‚é“ûŠà“]ˆÚ‘£i‹@\‚É‚¨‚¯‚éˆâ“`Žqƒlƒbƒgƒ[ƒN‚̉𖾌¤‹†‘ã•\ŽÒ
  4. ’|“c@ƒ@Œ¤‹†•ª’SŽÒ:‚…@—•Ar–ØŒc•FA”‘q“Ö•vA’|“c@ÈD•½¬27”N“x@Šw’·“Á•Ê‹¤“¯ƒvƒƒWƒFƒNƒgŒ¤‹†@ƒqƒg––½ŒŒ”’ŒŒ‹…‚̐³ŠúŽYE‘ŽY‚É‚¨‚¯‚镪•ØŠJŽn‚ɑ΂·‚é–ðŠ„‚É‚Â‚¢‚Ä
  5. Œ¤‹†‘ã•\ŽÒ:¬Š}Œ´@‰xŽq (—«ƒXƒ|[ƒcŒ¤‹†ƒZƒ“ƒ^[‘åŠw‰@ƒXƒ|[ƒcŒ’N‰ÈŠwŒ¤‹†‰È‹³Žö)D•½¬27 ”N“x@•¶•”‰ÈŠwÈ@Ž„—§‘åŠwí—ª“IŒ¤‹†Šî”ÕŒ`¬Žx‰‡Ž–‹Æ —«ƒXƒ|[ƒcŒ¤‹†ƒZƒ“ƒ^[‚É‚¨‚¯‚鏗«ƒAƒXƒŠ[ƒgƒRƒ“ƒfƒBƒVƒ‡ƒ“ŠÇ—‚ÉŠÖ‚·‚錤‹†Šî”Ս\’z
  6. ˆäã‘(é‹Êˆã‘åƒQƒmƒ€ˆãŠwŒ¤‹†ƒZƒ“ƒ^[Eˆâ“`Žq§Œä•”–åE•”–å’·), •ª’SŒ¤‹†ŽÒF’|“c@ÈDŒŽŒo’²®‚ƃRƒ“ƒfƒBƒVƒ‡ƒ“ŠÇ—ƒvƒƒOƒ‰ƒ€ŠJ”­Œ¤‹†@ˆâ“`Žq‰ü•ÏŽÀŒ±“®•¨ƒ‚ƒfƒ‹‚ð—p‚¢‚½œE‹Ø“÷E‰^“®”\‚É‚¨‚¯‚éƒXƒeƒƒCƒhƒzƒ‹ƒ‚ƒ“‚Ì–ðŠ„@700–œ‰~D
  7. Œ¤‹†ŠJ”­‘ã•\ŽÒF‹gì—T”VA•ª’SŽÒF’|“c@ÈA‘¼D“ú–{ˆã—ÃŒ¤‹†ŠJ”­‹@\ˆÏ‘õŒ¤‹†@ã”琫—‘‘ƒ‚ª‚ñ‚Ì”D›s«‰·‘¶Ž¡—Â̑Ώۊg‘å‚Ì‚½‚ß‚Ì”ñƒ‰ƒ“ƒ_ƒ€‰»ŒŸØ“IŽŽŒ±
‰p•¶Œ´’˜
  1. Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, Takeda S, Inoue S.
    MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.
    Sci Rep. 2015 Jan 6;5:7641. doi: 10.1038/srep07641.
  2. Verstraeten BSE, Mijovic-Kondejewski J, Takeda J, Tanaka S, Olson DM.
    Canadafs pregnancy-related mortality rates: doing well but room for improvement.
    Clin Invest Med 2015;38:
  3. Makino S, Takeda J, Hirai C, Itakura A, Takeda S.
    Uterine balloon tamponade as a test to assess the further treatment.
    Acta Obstet Gynecol Scand. 2015 Feb 2. doi: 10.1111/aogs.12599.
  4. Kato T, Takashima A, Kasamatsu T, Nakamura K, Mizusawa J, Nakanishi T, Takeshima N, Kamiura S, Onda T, Sumi T, Takano M, Nakai H, Saito T, Fujiwara K, Yokoyama M, Itamochi H, Takehara K, Yokota H, Mizunoe T, Takeda S, Sonoda K, Shiozawa T, Kawabata T, Honma S, Fukuda H, Yaegashi N, Yoshikawa H, Konishi I, Kamura T; on behalf of Gynecologic Oncology Study Group of the Japan Clinical Oncology Group. FClinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A).@Gynecol Oncol. 2015 Feb 7. pii: S0090-8258(15)00591-0. doi:10.1016/j.ygyno.2015.01.548.
  5. Nishioka E, Hirayama S, Ueno T, Matsukawa T, Vigeh M, Yokoyama K, Makino S, Takeda S, Miida T.
    Relationship between maternal thyroid-stimulating hormone (TSH) elevation during pregnancy and low birth weight: A longitudinal study of apparently healthy urban Japanese women at very low risk.
    Early Hum Dev. 2015 Feb 9;91(3):181-185. doi: 10.1016/j
  6. Sone M, Nakajima Y, Woodhams R, Shioyama Y, Tsurusaki M, Hiraki T, Yoshimatsu M, Hyodoh H, Kubo T, Takeda S, Minakami H.
    Interventional radiology for critical hemorrhage in obstetrics: Japanese Society of Interventional Radiology (JSIR) procedural guidelines.
    Jpn J Radiol. 2015 Apr;33(4):233-40. doi: 10.1007/s11604-015-0399-0.
  7. Baburamani AA, Miyakuni Y, Vontell R, Supramaniam VG, Svedin P, Rutherford M, Gressens P, Mallard C, Takeda S, Thornton C, Hagberg H.
    Does Caspase-6 Have a Role in Perinatal Brain Injury?
    Dev Neurosci. 2015 Mar 24. [Epub ahead of print]
  8. Shimanuki Y, Mitomi H, Fukumura Y, Makino S, Itakura A, Yao T, Takeda S.
    Alteration of Delta-like ligand 1 and Notch 1 receptor in various placental disorders with special reference to early onset preeclampsia.
    Hum Pathol. 2015 Apr 16. pii: S0046-8177(15)00116-1. doi:
  9. Murakami M, Kobayashi T, Kubo T, Hata T, Takeda S, Masuzaki H.
    Experience with recombinant activated factor VII for severe post-partum hemorrhage in Japan, investigated by Perinatology Committee, Japan Society of Obstetrics and Gynecology.
    J Obstet Gynaecol Res. 2015 May 25. doi: 10.1111/jog.12712.
  10. Makino S, Takeda S, Kobayashi T, Murakami M, Kubo T, Hata T, Masuzaki H.
    National survey of fibrinogen concentrate usage for post-partum hemorrhage in Japan: Investigated by the Perinatology Committee, Japan Society of Obstetrics and Gynecology.
    J Obstet Gynaecol Res. 2015 May 27. doi: 10.1111/jog.12708.
  11. Ueki N, Takeda S, Koya D, Kanasaki K.
    The relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsia.
    Int J Endocrinol. 2015;2015:572713. doi: 10.1155/2015/572713. Epub 2015 Apr 27. Review.
  12. Hamamura K, Nonaka D, Ishikawa H, Banzai M, Yanagida M, Nojima M, Yoshida K, Lee LJ, Tanaka K, Takamori K, Takeda S, Araki Y.
    Simple quantitation for potential serum disease biomarker peptides, primarily identified by a peptidomics approach in the serum with hypertensive disorders of pregnancy.
    Ann Clin Biochem. 2015 Apr 2. pii: 0004563215583697.
  13. Ikuma S, Sato T, Sugiura-Ogasawara M, Nagayoshi M, Tanaka A, Takeda S.
    Preimplantation Genetic Diagnosis and Natural Conception: A Comparison of Live Birth Rates in Patients with Recurrent Pregnancy Loss Associated with Translocation.
    PLoS One. 2015 Jun 17;10(6):e0129958. doi: 10.1371/journal.pone.0129958.
  14. Makino S, Hirai C, Itakura A, Takeda S, Yoshikawa H, Li Z, Kawabata KI, Tanaka H.
    Evaluation of uterine blood flow: a new method using contrast-enhanced ultrasound.
    Eur J Obstet Gynecol Reprod Biol. 2015 Jun 4. pii: S0301-2115(15)00137-2. doi:
    10.1016/j.ejogrb.2015.04.009.
  15. Takeda, J, Kikuchi, I, Kono, A, Ozaki, R, Kumakiri, J, Takeda, SD
    Efficacy of short-term training for acquisition of basic laparoscopic skillsD
    Gynecology and Minimally Invasive Therapy@@Available online 26 June 2015
  16. Hiromi Yamada, Yoko Tabe, Kiyoshi Ishii, Yasuhisa Terao, Yohei Yamashita, Takashi Horii, Satoru Takeda, Akimichi Ohsaka
    Clinical Performance Evaluation of a High-Risk Human@Papillomavirus Genotyping Test gClinichip HPVh@Using Cervical Scrape Specimens.
    Clin. Lab. 2015;61:851-855
  17. Inagaki T, Kusunoki S, Tabu K, Okabe H, Yamada I, Taga T, Matsumoto A, Makino S, Takeda S, Kato K.
    Up-regulation of lymphocyte antigen 6 complex expression in side-population cells derived from a human trophoblast cell line HTR-8/SVneo.
    Hum Cell. 2015 Jul 30. [Epub ahead of print]
  18. Hara K, Fukumura Y, Saito T, Arakawa A, Okabe H, Takeda S, Yao T.
    A giant cord hemangioma with extramedullary hematopoiesis and elevated maternal serum human chorionic gonadotropin: a case report and review of the literature.
    Diagn Pathol. 2015 Sep 4;10(1):154. doi: 10.1186/s13000-015-0385-y.
  19. Lucas ES, Dyer NP, Murakami K, Lee YH, Chan YW, Grimaldi G, Muter J, Brighton PJ, Moore JD, Patel G, Chan JK, Takeda S, Lam EW, Quenby S, Ott S, Brosens JJ.
    Loss of Endometrial Plasticity in Recurrent Pregnancy Loss.
    Stem Cells. 2015 Sep 29. doi: 10.1002/stem.2222. [Epub ahead of print]
  20. Tanaka, A, Nagayoshi, M, Takemoto, Y, Tanaka, I, Kusunoki, H, Watanabe, S , Kuroda,K, Takeda, S, Ito, M, Yanagimachi, R
    Fourteen babies born after round spermatid injection into human oocytes
    PNAS 2015 ; published ahead of print November 2, 2015, doi:10.1073/pnas.1517466112
  21. Chigusa Y, Kawasaki K, Kondoh E, Mogami H, Ujita M, Fujita K, Tatsumi K, Takeda S, Konishi I.FSimvastatin inhibits oxidative stress via the activation of nuclear factor erythroid 2-related factor 2 signaling in trophoblast cells.
    J Obstet Gynaecol Res. 2015 Nov 10. doi: 10.1111/jog.12876.
  22. Kuroda K, Kitade M, Kumakiri J, Jinushi M, Shinjo A, Ozaki R, Ikemoto Y, Katoh N, Takeda S.FMinimum ovarian stimulation involving combined clomiphene citrate and estradiol treatment for in vitro fertilization of Bologna-criteria poor ovarian responders.
    J Obstet Gynaecol Res. 2015 Nov 10. doi: 10.1111/jog.12862.
  23. Suzuki S, Takeuchi T, Okano T, Kamiya N, Sugiyama T, Ebine M, Matsuda H, Suzuki T, Okai T, Takeda S, Ochiai K, Kinoshita K.
    Problems of Perinatal Mental Health Care in Tokyo, Japan.
    J Clin Med Res. 2015 Dec;7(12):1013. doi: 10.14740/jocmr2371w. Epub 2015 Oct 23.
  24. Takagi K, Yamasaki M, Nakamoto O, Saito S, Suzuki H, Seki H, Takeda S, Ohno Y, Sugimura M, Suzuki Y, Watanabe K, Matsubara K, Makino S, Metoki H, Yamamoto T
    A Review of Best practice guide 2015 for care and treatment of hypertension in pregnancy. Hypertens Res Pregnancy 2015;3:65-103
‰p•¶‘à
  1. Takagi K, Yamasaki M, Nakamoto O, Saito S, Suzuki H, Seki H, Takeda S, Ohno Y, Sugimura M, Suzuki Y, Watanabe K, Matsubara K, Makino S, Metoki H, Yamamoto TDA Review of Best practice guide 2015 for care and treatment of hypertension in pregnancyDHypertens Res Pregnancy 2015;3:65-103
  2. Baburamani AA, Miyakuni Y, Vontell R, Supramaniam VG, Svedin P, Rutherford M, Gressens P, Mallard C, Takeda S, Thornton C, Hagberg HDDoes Caspase-6 Have a Role in Perinatal Brain Injury?DDev Neurosci. 2015;37:321-37
  3. Ueki N, Takeda S, Koya D, Kanasaki KDThe relevance of the Renin-Angiotensin system in the development of drugs to combat preeclampsiaDInt J Endocrinol. 2015;2015:572713. doi: 10.1155/2015/572713.
  4. Verstraeten BSE, Mijovic-Kondejewski J, Takeda J, Tanaka S, Olson DMDCanada's pregnancy-related mortality rates: doing well but room for improvementDClin Invest Med. 2015 6;38:E15-22
˜a•¶Œ´’˜
  1. “c‘ã —Ç•F @‘œ T–ç, ™–{ ‹Nˆê, –öÀ sG, ¬“‡ –L, ŒÜ“¡ —Ï•q, ¡¼ r‰î, –ko ^—, ”ª”ö —²Žj, â–{ ˆê”ŽD’°•ÂÇ‚𔭏ǂµ‚½‰ñ’°Žq‹{“à–ŒÇ‚Ì1—áD “ú–{ŠO‰ÈŒn˜A‡Šw‰ïŽ 40;122-127,2015
  2. ˆË“¡ ’Žu, –q–ì ^‘¾˜Y, •½ˆä ç—T, ŽR–{ —S‰Ø, ”‘q “Ö•v, ’|“c ÈD”DPE•ª•ØEŽYåñŠú‚ÌŒŒðÇðÇ—\–h–@‚̉ۑèD“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ïŽ,@2015; 24 : 47-52
  3. “í–Ø ‘Ži, ‘¾“c „Žu, ‹à“c —eG, Ž›”ö ‘׋v, ’|“c ÈDŽq‹{“à–ŒÇ«”X–E‚ÌŒo‰ßŠÏŽ@’†‚Ɉ««‰»‚ð‚«‚½‚µ‚½Ç—á‚ÌŒŸ“¢D“ú–{•wl‰ÈŽîᇊw‰ïŽGŽ@2015;33:29-35
  4. ìú±—D@ŒFØ‡@–ko^—@•“cŒbŽi@’nŽå½@´…‘€@Ž•½—R‹I@’r–{—TŽq@”öè—Œb@‘ºãŒ\—S@“c“‡‹±Žq@’|“cÈD• o‹¾‰ºŽèp‚É‚¨‚¯‚é“d“®ƒ‚ƒ‹ƒZƒŒ[ƒ^[‚ÌŽg—p‚ÉŠÖ‚·‚銳ŽÒˆÓŽ¯’²¸D“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽ@64: 557-564A2015
  5. ŽÂŒ´@ŽO’ÃŽqA–xàV@MA’nŽå@½A–ko@^—AŒFØ@‡A•“c@ŒbŽiA”öè@—ŒbAVé@ˆ²A’|“c@ÈDƒGƒ“ƒhƒJƒƒŒƒIƒ“®‚ð—p‚¢‚½• o‹¾‰º—‘‘ƒ”XŽî“Eop@8—á‚ÌŒŸ“¢D“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽA64F16-19, 2015
‰p•¶•ñ
  1. Makino S, Hirai C, Itakura A, Takeda S, Yoshikawa H, Li Z, Kawabata K, Tanaka HDEvaluation of uterine blood flow: a new method using contrast-enhanced ultrasoundDEur J Obstet Gynecol Reprod Biol. 2015; 191:143-4.
  2. Makino S, Takeda J, Hirai C, Itakura A, Takeda SDUterine balloon tamponade as a test to assess further treatmentDActa Obstet Gynecol Scand. 2015; 94:556
˜a•¶•ñ
  1. ŒFØ@‡, ‹e’n ”Õ, ŒK’ß —Ç•½, ’|“c ÈD‘½”­«Žq‹{‹ØŽî‚¨‚æ‚ÑŽq‹{‘B‹ØÇ‚ð—L‚µ‚½Ç—á‚ɑ΂·‚éŽq‹{“®–¬ÇðpŒã‚É’vŽ€“I”xÇð‚𔭏ǂµ‚½1—áDŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ 521;45-50, 2015
  2. ‹à“c —eG, “¡–ì ˆê¬, Ž•½ ’•¶, “í–Ø ‘Ži, –Ø‘º ”üˆ¨, Ž›”ö ‘׋v, –ko ^—, ”‘q “Ö•v, ’|“c ÈD•ª—tóèòŠÇ‘B‰ßŒ`¬‚ɑ΂µ• o‹¾‰ºŽq‹{‘S“Eop‚ðs‚¢pŒãÅ¬•Î˜ßŒ^”S‰t«‘BŠà‚Ɛf’f‚µ‚½1—áD“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽ 64:246-252, 2015
  3. ‚‹´@‰ë–ç, ¬–ì@‹`‹v, ‘匴@Œ’, ¼‰i@–΍„, ’·ˆä@’q‘¥, ‘ºŽR@Œh•F, ‚ˆä@‘×, Ö“¡@³”Ž, ”nê@ˆêŒ›, ŠÖ@”Ž”VD•ê‘ÌŽ€–S‚ÉŽŠ‚Á‚½ŽüŽYŠúS‹ØÇ‚Ì1—áDé‹ÊŒ§ˆãŠw‰ïŽGŽ, 50: 278-283, 2015
  4. ‚‹´@‰ë–ç, ‹à“c@—eG, Î“c@‚ä‚è, ŽO—ց@ˆ»Žq, ’·ˆä@çŽ÷, “í–؁@‘Ži, –Ø‘º@”üˆ¨, Ž›”ö@‘׋v, ”‘q@“Ö•v, ’|“c@ÈDˆ««•F•\”çŽî‚ðŒ_‹@‚ɐf’f‚ÉŽŠ‚Á‚½• –ŒŠà‚̈ê—áDŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ïŽ, 52F719-726, 2015
  5. •ìKAŽR–{—S‰ØA‘ºãŒ\—SA´…‘€A–q–ì^‘¾˜YA”‘q“Ö•vA’|“cÈD‘Šú‚Ì‘OŠú”j…‚É‚æ‚é’·Šú—r…‰ß­‚ÉŠÖ‚í‚炸A—ǍD‚ȐV¶Ž™—\Œã‚ð’悵‚½ˆê—áD“Œ‹žŽY•wl‰ÈŠw‰ï‰ïŽ,64:437-441, 2015
  6. ŽÂŒ´ ŽO’ÃŽq, –xàV M, ’nŽå ½, –ko ^—, ŒFØ@‡, •“c ŒbŽi, ”öè —Œb, Vé ˆ², ’|“c ÈDƒGƒ“ƒhƒJƒƒŒƒIƒ“‚ð—p‚¢‚½• o‹¾‰º—‘‘ƒ”XŽî“Eop8—á‚ÌŒŸ“¢D“Œ‹žŽY‰È•wl‰ÈŠw‰ï‰ïŽ 64;16-19, 2015
˜a•¶‘à
  1. ’|“c@ÈDˆÙŠ«”DPD¡“ú‚ÌŽ¡—ÃŽwj2015 57: 1231 ˆãŠw‘‰@
  2. ’|“c@ÈD“àfŠŒ©‚Å‚ÌŽ™“ª‚̍‚‚³‚Ì•\Œ»‚ÉŠÖ‚·‚é’ñŒ¾@\\ˆÀ‘S‚È‹}‘¬‹•Øp‚Ì‚½‚߂Ɂ\\D“ú–{ŽY‰È•wl‰ÈŠw‰ïŽ67F2052|55A2015
  3. ’|“c@ÈD”D•w‹~‹}‘Ήž‚ÌŽÀ‘H‚ƈã—ÃVƒXƒeƒ€\’z‚Ì‚½‚߂Ɂ@Šw‰ï‚ÌŽæ‚è‘g‚݁@“ú–{ŽY‰È•wl‰ÈŠw‰ïŽüŽYŠúˆÏˆõ‰ïDŽY•w‚ÌŽÀÛ64F1177A2015
  4. ’|“c@ÈDŽèp‚ª‚¢‚ç‚È‚¢H!V‚µ‚¢äTƒ_ƒCƒŒ[ƒ^|‚ð—p‚¢‚½”ñŠÏŒŒ“I‘¢äTpD“ú–{ˆãŽ–V•ñ4778F48A2015
  5. ’|“c@ÈD“àfŠŒ©‚Å‚ÌŽ™“ª‚̍‚‚³‚Ì•\Œ»‚ÉŠÖ‚·‚é’ñŒ¾\\ˆÀ‘S‚È‹}‘¬‹•Øp‚Ì‚½‚߂Ɂ\\D“ú–{ŽY‰È•wl‰ÈŠw‰ïŽ67F2052|55, 2015
  6. ’|“c@ÈD”D•w‹~‹}‘Ήž‚ÌŽÀ‘H‚ƈã—ÃVƒXƒeƒ€\’z‚Ì‚½‚߂Ɂ@Šw‰ï‚ÌŽæ‚è‘g‚݁@“ú–{ŽY‰È•wl‰ÈŠw‰ïŽüŽYŠúˆÏˆõ‰ïDŽY•w‚ÌŽÀÛ64F1177, 2015
  7. ’|“c@ÈDŽèp‚ª‚¢‚ç‚È‚¢H!V‚µ‚¢äTƒ_ƒCƒŒ[ƒ^|‚ð—p‚¢‚½”ñŠÏŒŒ“I‘¢äTpD“ú–{ˆãŽ–V•ñ4778F48, 2015
  8. ”‘q“Ö•vDŽüŽYŠúf—Âׂ©‚炸W •s‹K‘¥R‘ÌŒŸ¸—z«‚ð‚Ý‚Ì‚ª‚·‚ׂ©‚炸DŽüŽYŠúˆãŠw@45‘Š§†F34-36, 2015
  9. –ko^—DŽq‹{‹ØŽî‚ɑ΂·‚é’áNPŽ¡—Áy“ÁWz@• o‹¾‰ºŽq‹{‹ØŽîŠjop‚̃gƒsƒbƒNƒXD“ú–{ŽY‰È•wl‰ÈŠw‰ïŽGŽ 67:1411-1419, 2015,
  10. –ko^—AŒE^—R”üD—«ƒAƒXƒŠ[ƒg‚ւ̃Tƒ|[ƒg‚ðl‚¦‚é@ŠCŠO‚ÉŠw‚Ô‡A-ƒAƒƒŠƒJŽ‹Ž@ƒŠƒ|[ƒg-DCoaching clinic 5ŒŽ†F22-25, 2015
  11. –ko^—DŽq‹{“à–ŒÇ‚Ì–ò•¨—Ö@@2.Žá”N—«‚ÌŽq‹{“à–ŒÇ‚ÌŽ¡—ÁFŽèp—Ö@‚àŠÜ‚߂āDÅV—«ˆã—à 2: 66-73, 2015
  12. –ko^—D—«ƒAƒXƒŠ[ƒgŠO—ˆ‚̐ݗ§‚ÆŒ»ó@\—«ƒAƒXƒŠ[ƒg‚Ì’·Šú“I‚È‹£‹Z—ÍŒüã‚ð–ÚŽw‚µ‚ā\D‡“V“°‘åŠwŽY•wl‰È“¯‘‹‰ïŽ .23-24 2015
  13. Ž›”ö ‘׋v, –ko ^—, ’|“c ÈD•wl‰ÈŽèp‚ƌ㕠–Œ‰ð–U@• o‹¾‰ºŽèp‚É‚¨‚¯‚éˆÀ‘SŠmŽÀ‚ÈŽèp‚ðs‚¤‚½‚߂̍œ”՗Տ°‰ð–U‚Ì—‰ðDŽY•wl‰ÈŽèp 26;109-113, 2015
  14. –q–ì^‘¾˜YDy”D•w‹~‹}‘Ήž‚ÌŽÀ‘H‚ƈã—ÃVƒXƒeƒ€\’z‚Ì‚½‚߂Ɂz ŽY‰È‹~‹}‚Ì“ÁŽê«@ŠO‰Èˆ’uDŽY•wl‰È‚ÌŽÀÛ@64: 1141-1146, 2015
  15. –q–ì^‘¾˜Y@ˆîŠ_“OŒPD•ª•ØŒãŠë‹@“IoŒŒ‚É‚¨‚¢‚Ä‘‚ß‚Ì—AŒŒŽè”z‚ð‘Ó‚é‚ׂ©‚炸DŽüŽYŠúf—Âׂ©‚炸W@45; 362, 2015
  16. ŽR–{—S‰ØA”‘q“Ö•vA’|“c@ÈD”DP’†ŒãŠú@‘ÙŽ™Œ`‘ԈُíƒXƒNƒŠ[ƒjƒ“ƒOD—Õ•wŽY 69:632-638, 2015
  17. ’nŽå@½DERAS -ŽY•wl‰È—̈æ‚É‚¨‚¯‚éERAS-D—Տ°ŽGŽŠO‰È 77;175-179, 2015
  18. –xàV@MAŒFØ@‡A’|“c@ÈD•wl‰È—̈æ‚É‚¨‚¯‚é• o‹¾‰ºŽèp‚ÌŽå‚ȏpŽ®DŽèpŠÅŒìƒGƒLƒXƒp[ƒg@8G54-9, 2015
  19. “¡–ìˆê¬A’|“c@ÈD‹}«• Ç ‚æ‚­‚í‚©‚錟¸‚Ɛf’fDŽY‚Æ•w 28 suppl.:420-423, 2015
  20. •½ˆäç—T@”‘q“Ö•vD•wl‰È‡•¹Ç‚ւ̑Ήž‚̃Rƒc‚Æ—Ž‚Æ‚µŒŠDŽüŽYŠúˆãŠw@45F756-758, 2015
  21. •½ˆäç—T@–q–ì^‘¾˜YDèòŠÇ”DP‚ÆCesarean Scar Pregnancy(CSP)‚ւ̑ΉžDŽüŽYŠúˆãŠw@45F1057-1060, 2015
  22. •½ˆäç—T@–q–ì^‘¾˜YDDVT”­Ç—\–h‚ð‚©‚Ë‚½’鉤ØŠJpŒãáu’ÉŠÇ—‚̍H•vDŽüŽYŠúˆãŠw@45F1758-1760, 2015
  23. •½ˆäç—T@’|“cÈD4. tŽ¾Š³‡•¹”DP\B. ‡•¹Ç”DP‚ÌŠÇ—‚ÆŽ¡—ÁDŽY‰È•wl‰ÈŽ¾Š³ÅV‚ÌŽ¡—à 2016-2018F115
  24. —é–Ø•qŽjE’ßú±”ü“¿E¼–{’¼’Ê Dˆâ“`«Ž¾Š³‚ÌŒ´ˆö‹†–¾‚É‚¨‚¯‚鎟¢‘ãƒV[ƒNƒGƒ“ƒX‚Ì—L—p« Dˆâ“`ŽqˆãŠw 28;32-37, 2015
  25. —é–Ø•qŽjE¼–{’¼’Ê DWDR45•ÏˆÙ‚ª‚Ђ«‹N‚±‚·“S’¾’…«_Œo•Ï«Ž¾Š³SENDAD“à•ª”åE“œ”A•aE‘ãŽÓ“à‰È@40;465-469, 2015
  26. ˆîŠ_“OŒP –q–ì^‘¾˜YD—AŒŒ»Ü‚Ì‘I’è–@EƒNƒƒXƒ}ƒbƒ`–@E“Š—^Žž‚Ì’ˆÓ‚ð‚í‚·‚ê‚é‚ׂ©‚炸DŽüŽYŠúf—Âׂ©‚炸W 45:, 360-361, 2015
  27. ’|“c@ƒA’|“c@ÈD”DP‡•¹Ç@‚—î”DP‚Æ‘O’u‘ٔՁDŽY•w‚ÌŽÀÛ64:509-515A2015
  28. ’|“cƒA’|“cÈD‚—î”DP‚ð’m‚éDŽY•wl‰È‚ÌŽÀÛ 64, 2015
  29. ’|“cƒA’|“cÈDŽüŽYŠúf—Âׂ©‚炸W@‹zˆø•ª•Ø‚ð‚È‚ñ‚Æ‚È‚­Ž{s‚·‚é‚ׂ©‚炸DŽüŽYŠúˆãŠw@45‘Š§†:388-390, 2015
  30. ’|“cƒA’|“cÈDŽüŽYŠúf—Âׂ©‚炸W@“àfŠŒ©‚ª•s³Šm‚È‚Ü‚Ü‚ÅççŽq•ª•Ø‚ðs‚¤‚ׂ©‚炸DŽüŽYŠúˆãŠw@45‘Š§†: 391-392, 2015
  31. ’r–{@—TŽqA’|“c@ÈD• o‹¾‰ºŽq‹{‹ØŽîŠjop‚É‚¨‚¯‚é‹ØŽîŠj‚̉ñŽû•û–@D“ú–{ˆãŽ–V•ñ,@4781F54A2015
  32. ‘ºã Œ\—S , ’|“c ÈDŒŒŠÇŒ‹ãF–@ : stepwise devascularization (“ÁW ŽY‰ÈŽèp ŽÀ’n—Տ°‚̃Rƒc) -- (ŽYåñŽžEŽYåñ‘åoŒŒ‚ւ̑΍ô)DŽüŽYŠúˆãŠw 45, 1123-1125, 2015
  33. ˆÉ“¡ , ¼‘º—DŽqCˆÉ“¡‹±•FCÜ–Î ²DŠà“àüˆÛ‰è×–E‚ÆŠàˆ««‰»wŒÄ‹zxDŒÄ‹zŒ¤‹† 34:758-766, 2015
  34. Ü–Î ², ¼‘º—DŽq, –{‘½ˆê‹M, Nadila WaliDŠà“àüˆÛ‰è×–E‚ÆŠàˆ««‰»@Šà‚Ì”÷¬ŠÂ‹«‚Æ•W“IŽ¡—ÁDwŽÀŒ±ˆãŠwx—r“yŽÐ 33: 73-80, 2015
  35. Ü–Î ²@¼‘º—DŽqCˆÉ“¡‹±•FC\‡WìDüˆÛ‰»•a‘Ô‚ÆŠàˆ««‰»DwŒÄ‹zŠí“à‰Èx27:142-148, 2015
˜a•¶’˜‘
  1. ’|“c@Èi•]‰¿ˆÏˆõj•ÒW@‹}«• Çf—ÃKƒCƒhƒ‰ƒCƒ“o”ňψõ‰ïD‹}«• Çf—ÃKƒCƒhƒ‰ƒCƒ“2015DˆãŠw‘‰@@2015”N3ŒŽ1“ú
  2. ’|“c@Èi•ª’Sj •ÒW@“ú–{”DP‚ŒŒˆ³Šw‰ïD”DP‚ŒŒˆ³ÇŒóŒQ‚̐f—ÃŽwj2015DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N4ŒŽ1“ú
  3. •½ˆäç—TA’|“c@Èi•ª’S)D”DPŒãŠúAŽö“ûŠú ‰ž—p‰h—{Šw@‘æ10”Ł@ƒ‰ƒCƒtƒXƒe[ƒW‚©‚ç‚Ý‚½lŠÔ‰h—{ŠwDˆãŽ•–òo”Ł@2015”N3ŒŽ20“ú
  4. ’|“c@ÈAŠÖ@”Ž”Vi•ÒWjDŽ™“ª‰º~“x‚Ì•]‰¿‚ÆççŽq‹•Øp@ˆÀ‘SEŠmŽÀ‚È‹zˆøEççŽq•ª•Ø‚Ì‚½‚߂ɁDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N4ŒŽ1“ú
  5. ’|“c@È@ŠÄC “ú–{ŽY‰È–ƒŒŠw‰ïD–³’É•ª•Ø‚Ì‚·‚·‚߁D–ˆ“úV•·o”Ł@2015”N4ŒŽ1“ú
  6. –q–ì^‘¾˜YA’|“c@È i‹¤’˜E’S“–•ÒWjA•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 22@Žèp‚ð—v‚·‚éŽY•wl‰È‹~‹}@‚±‚ñ‚È‚Æ‚«‚Ç‚¤‚·‚éHíˆÊ‘Ù”Õ‘Šú”—£‚̒鉤ØŠJpDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N5ŒŽ10“ú
  7. ˆË“¡’ŽuA’|“c@ƒA’|“c@Èi‹¤’˜E’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 22@Žèp‚ð—v‚·‚éŽY•wl‰È‹~‹}@‚±‚ñ‚È‚Æ‚«‚Ç‚¤‚·‚éH’oŠÉoŒŒiŒoäT•ª•ØjDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N5ŒŽ10“ú
  8. ‹e’n@”ՁAŒFØ@‡A’|“c@Èi‹¤’˜E’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 22@Žèp‚ð—v‚·‚éŽY•wl‰È‹~‹}@‚±‚ñ‚È‚Æ‚«‚Ç‚¤‚·‚éHŽq‹{“à–ŒÇ«—‘‘ƒ”X–EDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N5ŒŽ10“ú
  9. ’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’å@’†‘l–¯‰ð•úŒR‘æ202ˆã‰@•wŽY‰È•›‹³ŽöDOGS Now 3 (’†‘”Å)@• Ž®’PƒŽq‹{‘S“Ep@Šî–{Žè‹Z‚ÌŠ®‘Sƒ}ƒXƒ^[ ‘O’u‘ٔՁA‘O’u–ü’…‘ٔՁDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@’†‘”Å2016”N6ŒŽ
  10. “c’†—˜—²A’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’å@’†‘l–¯‰ð•úŒR‘æ202ˆã‰@•wŽY‰È•›‹³ŽöDOGS Now 3 (’†‘”Å)@• Ž®’PƒŽq‹{‘S“Ep@Šî–{Žè‹Z‚ÌŠ®‘Sƒ}ƒXƒ^[ ’鉤ØŠJŽž‚Ì‘å—ʏoŒŒ‚̑Ώˆ–@DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@’†‘”Å2016”N6ŒŽ
  11. –q–ì^‘¾˜YA’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’å@’†‘l–¯‰ð•úŒR‘æ202ˆã‰@•wŽY‰È•›‹³ŽöDOGS Now 3@(’†‘”Å)@• Ž®’PƒŽq‹{‘S“Ep@Šî–{Žè‹Z‚ÌŠ®‘Sƒ}ƒXƒ^[ p’†EpŒãŠÇ—DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@’†‘”Å2016”N6ŒŽ
  12. Ž›”ö‘׋vA–q–ì^‘¾˜YA’|“c@È (•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚̍H•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mŽ¯ Žèp’†‚Ì‹}•Ï‘Ήž@‘åoŒŒ‚ւ̑Ήž@ŽY•wl‰Èˆã‚Ì—§ê‚©‚çDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  13. –q–ì^‘¾˜YA’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚̍H•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mŽ¯ Žèp’†‚Ì‹}•Ï‘Ήž@p’†S’âŽ~‚Æ‚»‚̑ΉžDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  14. ’nŽå@½A’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚̍H•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mŽ¯ ŽüpŠúŠÇ—‚Ì•K{’mŽ¯@Enhanced Recovery After Surgery; ERAS@•wl‰È• o‹¾Žèp‚Ö‚Ì“K‰žDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  15. Ž•½’•¶A’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚̍H•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mŽ¯ “à‰ÈŽ¾Š³‡•¹—á‚ÌŽüpŠúŠÇ—@SEŒŒŠÇŽ¾Š³DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  16. “¡–ìˆê¬A’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚̍H•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mŽ¯ “à‰ÈŽ¾Š³‡•¹—á‚ÌŽüpŠúŠÇ—@ŒÄ‹zŠíŽ¾Š³DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  17. ‹à“c—eGA’|“c@È(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾AŠÄ–ó@ŒO‹Ê’åDOGS Now 23@Šo‚¦‚Ä‚¨‚«‚½‚¢Žèp‚̍H•v‚ÆŽüpŠúŠÇ—@‚³‚Ü‚´‚܂ȋǖʂŖ𗧂Žè‹Z‚Æ’mŽ¯ “à‰ÈŽ¾Š³‡•¹—á‚ÌŽüpŠúŠÇ—@ŠÌŽ¾Š³DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N8ŒŽ10“ú
  18. ’|“c@È@(•ª’SA’S“–•ÒWj•½¼—SŽiA¬¼ˆè¶AŸN–͖ؔ¾DOGS Now 24 “`‚¦‚½‚¢Ž„‚ÌŽèp@Art‚ÆScience‚Ì—Z‡@“®‰æ‚Å“`Žö‚·‚éŽY•wl‰ÈŽèp‚Ì‹†‚Ý ‹‘åŽq‹{èò•”‹ØŽîŠjopDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N11ŒŽ10“ú
  19. •½¼—SŽi@ŸN–͖ؔ¾@¬¼ˆè¶@’|“c@ÈDOGS Now 24 “`‚¦‚½‚¢Ž„‚ÌŽèp@Art‚ÆScience‚Ì—Z‡@“®‰æ‚Å“`Žö‚·‚éŽY•wl‰ÈŽèp‚Ì‹†‚Ý ŽY•wl‰ÈŽèp‚ð‹†‚ß‚é@‰·ŒÌˆçV‚©‚çg‚í‚´h‚𖁂­ƒRƒcDƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N11ŒŽ10“ú
  20. ’|“c@ƒA’|“c@ÈDíˆÊ‘Ù”Õ‘Šú”—£@MFICUƒ}ƒjƒ…ƒAƒ‹ ‘S‘ŽüŽYŠúˆã—ØA—‹¦‹c‰ï@•Ò’˜DƒƒfƒBƒJo”Ł@2015”N8ŒŽ1“ú
  21. ’|“c@ÈD‡“V“°Ž®–³’É•ª•ØDƒkƒ“ƒN@2015”N11ŒŽ25“ú
  22. ’|“c@ƒA’|“c@ÈDŽY‰ÈoŒŒ/oŒŒ«ƒVƒ‡ƒbƒN/Á”‹ÃŒÅáŠQ@“Á•Ê•ÒW@‰ªŒ³˜a•¶@EREICU‚Å‚Ì–ò‚ÌŽg‚¢•ûEl‚¦•û@ƒGƒLƒXƒp[ƒg‚ÌŽÀ‘H‚Ɣ錍‚ÉŠw‚ԁ@2016\f17D‹~‹}EW’†Ž¡—à 27 :e261-267, 2015
  23. –q–ì^‘¾˜Y@’|“c ÈDŽ©•ª‚̃ŠƒXƒN‚ð’m‚Á‚ÄŽY‰@‚ð‘I‚Ú‚¤DHUMAN + —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[
  24. –q–ì^‘¾˜YD”DP‚ŒŒˆ³ÇŒóŒQ‚̐f—ÃŽwj2015DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N3ŒŽ24“ú
  25. –q–ì^‘¾˜YD—§‰ï‚¢oŽYA‚»‚Ì‘O‚É‚Å‚«‚邱‚Æ‚Á‚āHDBaby+
  26. –q–ì^‘¾˜Y@’|“c ÈDŽ©•ª‚̃ŠƒXƒN‚ð’m‚Á‚ÄŽY‰@‚ð‘I‚Ú‚¤DHUMAN + —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[ 2015
  27. •½ˆäç—T@’|“cÈD‚¨‚È‚©‚Ì‚Í‚èE’ɂ݃KƒCƒhƒ‰ƒCƒ“DHUMAN+, —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[2015, P32
  28. •½ˆäç—T@’|“cÈDØ”——¬ŽYEØ”—‘ŽY‚ÆŒ¾‚í‚ꂽ‚çDHUMAN+, —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[2015, P40-41
“Á•Êu‰‰Eµ‘ҍu‰‰“™ i‘Ûj
  1. Mari KitadeDReduced Port Surgery (RPS) for Benign TumorDAPAGE workshop (Shanghai, China@2015/3/27-28)
  2. Mari KitadeDIntroduction of tne animal training for laparoscopic surgeryDAPAGE-JSGOE Workshop@(Fukuoka, Japan 2015,8)
  3. Kitade M, Kumakiri J, Kuroda K, Jinushi M, Takeda SDOptimal Management in DIE@Surgical Management and Pathological Findings for DIE and CRE (Colorectal Endometriosis)DAPAGE 16th Annual Congress (Beijing, China 2015/11/5-8).
  4. Oota TDPort site metastasis in laparoscopic surgery. ~etiology and prevention~DAPAGE workshop (Shanghai, China@2015/3/27-28)
  5. Keiji KurodaDElevated serum TSH is associated with decreased AMH in infertile women of reproductive ageDThe 22nd World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), (Budapest Hungary, 2015/9/17-19)
“Á•Êu‰‰Eµ‘ҍu‰‰“™ i‘“àj
  1. ’|“c@ÈD¶ŠUŒ¤CƒvƒƒOƒ‰ƒ€@“ú–{ŽY•wl‰Èˆã‰ï‹¤“¯ƒvƒƒOƒ‰ƒ€/ 4. •ª•ØŠÇ—‚ÌŠî–{‚ðŒ©’¼‚·u“àfŠŒ©‚Å‚ÌŽ™“ª‚̍‚‚³‚Ì•\Œ»‚ÉŠÖ‚·‚é’ñŒ¾v|ˆÀ‘S‚È‹}‘¬‹•Øp‚Ì‚½‚߂Ɂ|D‘æ67‰ñ“ú–{ŽY‰È•wl‰ÈŠw‰ïŠwp‘ (‰¡•l 2015/4/9-12)
  2. ’|“c@ÈA–ko^—D–ÍŒ^‚ðŽg‚Á‚½ççŽqE‹zˆø•ª•Ø,ƒhƒ‰ƒCƒ‰ƒ{‚ð—p‚¢‚½•wl‰È• o‹¾‰ºŽè‹ZuKD‘æ4‰ñŽY•wl‰ÈuÀŒ¤C‰ï@(“Œ‹ž 2015/5/16)
  3. ’|“c@ÈD‘ÙŽ™S”ƒ‚ƒjƒ^ƒŠƒ“ƒO‚Ì“Ç‚Ý•ûD‘æ2‰ñ‰z’JŽs—§•a‰@NSTŒ¤‹†‰ï (é‹Ê 2015/5/22)
  4. ’|“c@ÈDŽY‰ÈŠë‹@“IoŒŒ‚ւ̑Ήž@•ª•ØŽæ‚舵‚¢ˆêŽŸŽ{Ý‚ł̑ΉžD“Œ‹ž—Žqˆã‘åŽY•wl‰ÈuÀ“¯–å‰ï‘‰ï@(“Œ‹ž 2015/6/13)
  5. ’|“c@ÈD‹ß–¢—ˆ‚ÌŽüŽYŠúˆã—ÁD‘æ17‰ñ“ú–{•ê«ŠÅŒìŠw‰ïŠwpW‰ï@(“Œ‹ž 2015/6/28)
  6. ’|“c@ÈDŽY‰ÈŠë‹@“IoŒŒ‚̑Ήž@‹ÇŠŽ~ŒŒ‚©ŒŒ—¬ŽÕ’f‚©D‘æ34‰ñŽOdŒ§¶ŠU‹³ˆç“Á•ÊŒ¤CƒZƒ~ƒi[@(ŽOd 2015/9/3)
  7. ’|“c@ÈD”DP‚ŒŒˆ³ÇŒóŒQ‚ÌŠÇ—D‘æ7‰ñ‹ž“sŽY•wl‰È‹~‹}f—ÃŒ¤‹†‰ï@(‹ž“s 2015/10/4)
  8. ’|“c@ÈDŽY‰È‹~‹}‚ƍŋ߂̓®ŒüD•½¬27”N“xŒFŒ§•ê‘Ì•ÛŒì–@Žw’èˆãŽtŒ¤C‰ï@(ŒF–{ 2015/11/7)
  9. ’|“c@ÈDŽY‰ÈŠë‹@“IoŒŒ‚̑ΉžDÎìŒ§ŽY•wl‰Èˆã‰ïEÎìŒ§ŽY‰È•wl‰ÈŠw‰ï“Á•Êu‰‰‰ï@(‹à‘ò 2015/12/13)
  10. ’|“c@ÈDŽ„‚ÌŽY•wl‰ÈŽèpŒ¤C@\\Ž¸”s‚ƍH•v\\D–¼ŒÃ‰®‘åŠw‘åŠw‰@ˆãŠwŒnŒ¤‹†‰È@(–¼ŒÃ‰® 2015/12/17)
  11. –ko^—AŒFØ‡A•“cŒbŽiA’nŽå½A’|“cÈDˆÀ‘S‚È• o‹¾‰ºƒ_ƒOƒ‰ƒXâ|ŠJ•úp‚ׂ̈̍œ”Õ‰ð–U‚Ì’mŽ¯‚ƃXƒgƒ‰ƒeƒW[D‘æ36‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï @(“Œ‹ž 2015/1/24-25)
  12. –ko^—D• o‹¾Žèp‚Ì‘n‘¢A‰üŠvA ‚»‚µ‚Ä–¢—ˆ @-•“à—T”V‚Ì7‚‚̋³‚¦- (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[jD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  13. –ko^—DƒgƒbƒvƒAƒXƒŠ[ƒg‚©‚çŠw‚ÔŒŽŒo‚Ì•s’²Ž•ž‚̔錍|—«‚ÌQOLŒüã‚ÉŒü‚¯‚ā| eŽq‹{“à–ŒÇf(Žs–¯ŒöŠJuÀjD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  14. –ko^—D—«ƒAƒXƒŠ[ƒg‚ÌŒŽŒoˆÙí‚Æ”æ˜JœÜ@\‹£‹ZƒpƒtƒH[ƒ}ƒ“ƒXŒüã‚Ì‚½‚ß‚ÉŽ„’B‚ª‚Å‚«‚鎖\Dç—tŽsŽs–¯ŒöŠJuÀ@(ç—t)
  15. –ko^—D‡@• o‹¾‰ºŽq‹{‘ÌŠàŽèp‚Ì —§‚¿ã‚°‚Ü‚Å‚ÌŒoˆÜ‚ƃgƒŒ[ƒjƒ“ƒOA‡Aƒpƒ‰ƒŒƒ‹–@‚ōs‚¤ • o‹¾‰ºŽq‹{‘ÌŠàŽèp -Žèp‚̃Xƒgƒ‰ƒeƒW[‚ƍ‡•¹Ç‘΍ô-DŽq‹{‘ÌŠàƒZƒ~ƒi[@(“Œ‹ž)
  16. –ko^—D‡@• o‹¾‰ºŽq‹{‘ÌŠàŽèp‚Ì —§‚¿ã‚°‚Ü‚Å‚ÌŒoˆÜ‚ƃgƒŒ[ƒjƒ“ƒOA‡Aƒpƒ‰ƒŒƒ‹–@‚ōs‚¤ • o‹¾‰ºŽq‹{‘ÌŠàŽèp -Žèp‚̃Xƒgƒ‰ƒeƒW[‚ƍ‡•¹Ç‘΍ô-DŽq‹{‘ÌŠàƒZƒ~ƒi[ (‰ªŽRE‘q•~)
  17. –ko^—D’†Œã”N‚É‚¨‚¯‚éŽq‹{“à–ŒÇ «”X–E‚ÌŽæ‚舵‚¢\Šà‰»‚̃ŠƒXƒN‚ÆŽèp—Ö@\D‘æ6‰ñ—«ƒzƒ‹ƒ‚ƒ“ˆË‘¶«Ž¾Š³Œ¤‹†‰ï (“Œ‹žj
  18. –ko^—D—«‚̃‰ƒCƒtƒXƒe[ƒW‚ðˆÓŽ¯‚µ‚½ Žq‹{“à–ŒÇ‚̃}ƒl[ƒWƒƒ“ƒgD”ŸŠÙ“àŽ‹‹¾Œ¤‹†‰ï i”ŸŠÙj
  19. –ko^—D• o‹¾ŽèpƒXƒLƒ‹ƒAƒbƒv‚̃Rƒc‚Æ‹³ˆç–@ `“àŽ‹‹¾‹Zp”F’èŽæ“¾‚܂ł̐S\‚¦‚ÆŽw“±ˆã‚Ì‚ ‚è•û`DŽœŒbˆã‰È‘åŠwW’k‰ï i“Œ‹žj
  20. –ko^—D—«ƒAƒXƒŠ[ƒg‚̏”–â‘è@\—«ƒAƒXƒŠ[ƒg‚ÌŽOŽå’¥‚ÆŒŽŒoŽž‚Ì•s’²\D‰¡•lˆã‰ï’è—á‰ï i‰¡•lj
  21. –ko^—D[•”Žq‹{“à–ŒÇ‚Æ”X–E«‘B‹ØÇ‚Ìpathogenesis‚©‚ç‚Ý‚½ŠÇ—ŽwjDJapan Endometriosis Forum i“Œ‹žj
  22. –ko^—D—«ƒAƒXƒŠ[ƒg‚̈ãŠw“I‚ȏ”–â‘è@ [‹£‹ZƒpƒtƒH[ƒ}ƒ“ƒXŒüã‚Ì‚½‚ß‚ÉŽ„’B‚ª‚Å‚«‚鎖[DŒc‰ž‘åŠwƒXƒ|[ƒcˆãŠwŒ¤‹†‰ï i‰¡•lj
  23. –ko^—D“]ˆÚ”\‚ðŠl“¾‚µ‚½benign cancer `Žq‹{“à–ŒÇ‚̃}ƒl[ƒWƒƒ“ƒg‚Æ •a—Šw“IlŽ@`D‘æ113‰ñ‚¨’ƒ‚̐…‚ª‚ñŠwƒAƒJƒfƒ~ƒA@(“Œ‹ž 2015/4/15)
  24. –ko^—AŒFØ‡A•“cŒbŽiA’nŽå½A’|“cÈD40Î—«‚ÌŽq‹{‹ØŽîE Žq‹{“à–ŒÇ‚ÌŽæ‚舵‚¢[—«‚Ì”N—î‚ƃ‰ƒCƒtƒXƒ^ƒCƒ‹‚É‘¦‚µ‚½Ž¡—ÃŽwj‚Ì’ñˆÄ[D‘æ30‰ñ“ú–{—«ˆãŠw‰ïŠwpW‰ï (–¼ŒÃ‰® 2015/11/7-8)
  25. –ko^—AŒFØ‡A•“cŒbŽiA’nŽå½A’|“cÈD•wl‰È—̈æ‚É‚¨‚¯‚é2‘åƒ|[ƒg”z’u‚Ì“Á«‚ÆŽw“EpŽ®‚ÌŒŸ“¢D‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (‘åã 2015/12/10-12)
  26. Ž›”ö@‘׋vDICT‚Ɛl‚ÅŒq‚®‚ª‚ñˆã—ÈېVƒvƒ‰ƒ“@u•wl‰È‚ª‚ñŽ¡—Âɂ¨‚¯‚é• o‹¾Žèp‚Ì‚ ‚è•û‚Æ“W–]v@D129Žq‹{‘Ì‚ª‚ñ‚ɑ΂·‚é’áNP‰»Ž¡—Âւ̎Ž‚݁D•½¬27•¶•”‰ÈŠwÈ‚ª‚ñƒvƒƒtƒFƒbƒVƒ‡ƒiƒ‹—{¬Šî”Ր„iƒvƒ‰ƒ“ (ŠâŽè 2015/9/2)
  27. Ž›”ö@‘׋vD‚±‚ê‚©‚çŽn‚ß‚él‚Ì‚½‚ß‚Ì• o‹¾‰ºƒŠƒ“ƒpßŠs´p‚̍H•v‚Ƒ΍ôD‘æ3‰ñ“Œ‹ž’áNP•wl‰ÈŽèpŒ¤‹†‰ï (“Œ‹ž 2015/2/21)
  28. ŒFØ‡DV¢‘ã‚Ì‹C• ƒ}ƒlƒWƒƒ“ƒgƒVƒXƒeƒ€-•wl‰È• o‹¾‰ºŽèp‚É‚¨‚¯‚é‹C• ŠÂ‹«‚̏d—v«-D‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (‘åã 2015/12/10-12)
  29. ŒFØ‡D[•”Žq‹{“à–ŒÇ‚ɑ΂·‚é• o‹¾Žèp@ˆÀ‘S«‚ƍČ»«‚ÌŒüã‚ÉŒü‚¯‚Ä ƒ_ƒOƒ‰ƒXâ|[•”Žq‹{“à–ŒÇ‚ɑ΂·‚é• o‹¾‰ºŽèp‚̈Ӌ`D‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  30. ŒFØ‡DElephant in the abdominal cavity`“d“®ƒ‚ƒ‹ƒZƒŒ[ƒ^[‚É‚æ‚éˆÀ‘S‚ÈŒŸ‘̉ñŽû‚ð–ÚŽw‚µ‚ā`D‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  31. ŒFØ‡D‹@”\‰·‘¶‚ð–Ú“I‚Æ‚µ‚½Žq‹{“à–ŒÇ‚ɑ΂·‚é• o‹¾‰ºŽèpD‘æ36‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï @(“Œ‹ž 2015/1/24-25)
  32. ‘¾“c„ŽuDƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“@APAGE Fellowship Training Course‚ÉŽQ‰Á‚µ‚āD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  33. Oota TDDoxorubicin hydrochloride and Bevacizumab for the patients with Platinum-taxane resistant Recurrent ovarian cancerD‘æ57‰ñ“ú–{•wl‰ÈŽîᇊw‰ï@(ŠâŽè, 2015/8/7-9)
  34. –q–ì^‘¾˜YDŽY‰È‘å—ʏoŒŒ‚ÌŽ~ŒŒ–@E—AŒŒ–@D‰ªŽR•ŽYŽt‰ï
  35. –q–ì^‘¾˜YDƒvƒƒQƒXƒeƒƒ“‚Æ‘ŽYD‘æ4‰ñƒvƒƒQƒXƒg\ƒQƒ“Œ¤‹†‰ï@(“Œ‹ž 20155/24)
  36. –q–ì^‘¾˜YDŽüŽYŠú—̈æ‚É‚¨‚¯‚éVTE‚ÌŒ»óD‡“V“°DVTŒ¤‹†‰ï
  37. –q–ì^‘¾˜YDŽüŽYŠú—̈æ‚É‚¨‚¯‚éÅ‹ß‚̃gƒsƒbƒNƒX (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‘æ12‰ñŽüŽYŠúƒƒ“ƒ^ƒ‹ƒwƒ‹ƒXŒ¤‹†‰ï@(“È–Ø 2015/10/31-11/1)
  38. –q–ì^‘¾˜YD’鉤ØŠJ‚Ì‹Ø‘w–D‡ (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[)D‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï@(•Ÿ‰ª 2015/7/10-12)
  39. –q–ì^‘¾˜Y@•½ˆäç—T@’|“c@ƒ@ˆÉ“¡—z‰î@ˆîŠ_“OŒP@”‘q“Ö•v@’|“c@ÈD‘O’u–ü’…‘Ù”Õ ‘O’u–ü’…‘ٔՂ̏p’†f’f‚Æ‚»‚ê‚ɉž‚¶‚½Ž~ŒŒ–@‚Ì‘I‘ðiƒVƒ“ƒ|ƒWƒEƒ€jD‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï@(•Ÿ‰ª 2015/7/10-12)
  40. –q–ì ^‘¾˜Y, •½ˆä ç—T, ’|“c ƒ, ²–ì–õŽq,“‡ŠÑ —m‘¾, ”‘q “Ö•v, ’|“c ÈD‘ÙŽ™S””ƒ‚ƒjƒ^ƒŠƒ“ƒO‚ÆŽžŠÔŽ²iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ38‰ñ•ê‘Ì‘ÙŽ™ˆãŠw‰ïŠwpW‰ï@(•Ê•{ 2015/10/29-30)
  41. –q–ì ^‘¾˜Y, •½ˆä ç—T, ’|“c ƒ, “‡ŠÑ —m‘¾, ˆË“¡ ’Žu, ”‘q “Ö•v, ’|“c ÈDŽq‹{“àƒ^ƒ“ƒ|ƒi[ƒf–@‚Ì—v’ú@“K—p‚ÆŒÀŠE Žq‹{“àƒoƒ‹[ƒ“ƒ^ƒ“ƒ|ƒi[ƒf‚É‚æ‚éŽ~ŒŒ‚ÌŒÀŠE‚Æ‚»‚̑΍ô@iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ130“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ïiç—t@2015/10/25-26j
  42. –q–ì^‘¾˜Y@ •ì@K ’|“c@ƒ •½ˆäç—T@“‡ŠÑ—m‘¾@ Šp‘qOs@”‘q“Ö•v ’|“c@ÈD‹}‘¬‹•ØiƒVƒ“ƒ|ƒWƒEƒ€jD‘æ119‰ñ“ú–{ŽY‰È–ƒŒŠw‰ïŠwpW‰ï@(“Œ‹ž 2015/11/28-29)
  43. –q–ì ^‘¾˜Y, •½ˆä ç—T, ”‘q “Ö•v, ’|“c È, Šp‘q OsDƒTƒuƒXƒyƒVƒƒƒŠƒeƒB[‚Æ‚µ‚Ä‚ÌŽY‰È–ƒŒ‚̈Ӌ`‚Æ‚Í ‡“V“°‘åŠw‚É‚¨‚¯‚éŽY‰È–ƒŒƒ`[ƒ€Ý—§‘OŒã‚ÌŽüŽYŠúˆã—Â̕ω»iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ35‰ñ—Տ°–ƒŒŠw‰ïŠwpW‰ï@(‰¡•l 2015/10/21-23)
  44. Keiji KurodaDElevated serum TSH is associated with decreased AMH in infertile women of reproductive ageDThe 22nd World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), Budapest Hungary, 2015”N9ŒŽ17“ú\19“ú
  45. •“cŒbŽiDŽq‹{“à–Œ’E—Ž–Œ‰»‰ß’ö‚É‚¨‚¯‚é ƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒhEƒŒƒ`ƒmƒCƒhƒVƒOƒiƒ‹Œo˜HD‘æ113‰ñ‚¨’ƒ‚̐…‚ª‚ñŠwƒAƒJƒfƒ~ƒA@(“Œ‹ž 2015/4/15)
  46. •“cŒbŽiD“V‘RŒ^ƒvƒƒQƒXƒeƒƒ“»Ü‚ÉŠú‘Ò‚·‚é ’…°‚â—¬ŽY‚Ö‚ÌŒø‰ÊDÅ“K‚È•s”DŽ¡—ÃJƒ“ƒtƒ@ƒŒƒ“ƒX (“Œ‹ž 2015/6/5)
  47. •“cŒbŽiD¶Bˆã—Âɂ¨‚¯‚é “V‘RŒ^ƒvƒƒQƒXƒeƒƒ“»Ü‚̐V‚½‚ȉ”\« [Žq‹{“à–Œ‚ÌŒ¤‹†ƒf[ƒ^‚ðŠî‚Ɂ[D‘æ33‰ñ“ú–{Žó¸’…°Šw‰ï‘‰ïEŠwpu‰‰‰ï (2015/11/26-27)
  48. •“cŒbŽiDESHRE Highlights: Implantation Potential & Fertility PreservationD‘æ33‰ñ“ú–{Žó¸’…°Šw‰ï‘‰ïEŠwpu‰‰‰ï (2015/11/26-27)
  49. •“cŒbŽiDƒ‰ƒCƒtƒXƒe[ƒW‚ɉž‚¶‚½ Žq‹{“à–ŒÇ‚̃}ƒl[ƒWƒƒ“ƒgD‰F“s‹{ŽY•wl‰Èˆã‰ï@“ñ‹à‰ï (“È–Ø 2015/11/13)
  50. ’nŽå@½DŽq‹{“à–ŒÇ‚ɑ΂·‚é• o‹¾‰ºŽèp@iƒXƒ|ƒ“ƒT[ƒhƒVƒ“ƒ|ƒWƒEƒ€jD‘æ36‰ñ“ú–{ƒGƒ“ƒhƒƒgƒŠƒI[ƒVƒXŠw‰ïŠwpu‰‰‰ï @(“Œ‹ž 2015/1/24-25)
  51. ’nŽå@½DˆÀ‘S‚ɍs‚¦‚éTLHE• o‹¾‰ºˆ««Žîᇎèp `ÅV‹@Ší‚ÌŽg—p•û–@‚ƃ|ƒCƒ“ƒg` (ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[jD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  52. ’nŽå@½DŽq‹{“à–ŒÇ‚ɑ΂·‚é• o‹¾‰ºŽèp@iƒVƒ“ƒ|ƒWƒEƒ€jD‘æ28‰ñ“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ï‘‰ï (‘åã 2015/12/10-12)
  53. ’nŽå@½DERASƒvƒƒgƒR[ƒ‹‚ð‚à‚Æ‚É• o‹¾‰ºŽèpŠ³ŽÒ‚ɑ΂µ‚Ä“±“ü‚µ‚½p‘OŒoŒû•â…‚Ì•û–@‚Æ‚»‚ÌŒø‰ÊD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  54. ”öú±—Œb, ŒFØ@‡,–ko^—, ’|“c@ÈDpŒãpoor ovarian responder ‰ñ”ð‚Ì‚½‚ß‚Ì —‘‘ƒƒ`ƒ‡ƒRƒŒ[ƒg”X–E‚ɑ΂·‚é • o‹¾‰º”X–E“Eop‚Ì“K‰ž‚̍člD‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  55. ’|“cƒA–q–ì^‘¾˜YA”‘q“Ö•vA’|“cÈD“–‰@‚É‚¨‚¯‚é• o‹¾‰ºŽq‹{‹ØŽîŠjopŒã”DP‚ÌŠÇ—D‘æ55“ú–{ŽY‰È•wl‰È“àŽ‹‹¾Šw‰ïŠwpW‰ï i‰¡•l@2015/09/10-12j
  56. ’|“cƒD–³’É•ª•Ø‚É‚¨‚¯‚镪•Ø‘£iD‘æ119‰ñ“ú–{ŽY‰È–ƒŒŠw‰ïŠwpW‰ï@(“Œ‹ž 2015/11/28-29)
‚»‚Ì‘¼iL•ñŠˆ“®‚ðŠÜ‚ށj
  1. ’|“c@ÈDŽq‹{‹ØŽîD¹‹³V•·7•Å2ŒŽ8“ú
  2. ’|“c@È •ÒW@ã–ì‰ë´D”­Š§‚ÉŠñ‚¹‚ā@‡“V“°Žj‚©‚ç‚Ý‚½ŽY•wl‰È—ïD‡“V“°‘åŠwˆãŠw•”ŽY•wl‰ÈŠwuÀ“¯‘‹‰ï@•½¬27”N4ŒŽ1“ú
  3. ’|“c@È •ÒW@ã–ì‰ë´D–{–@‰‚̒鉤ØŠJp‚Ə‡“V“°@‡“V“°Žj‚©‚ç‚Ý‚½ŽY•wl‰È—ïD‡“V“°‘åŠwˆãŠw•”ŽY•wl‰ÈŠwuÀ“¯‘‹‰ï@•½¬27”N4ŒŽ1“ú
  4. ’|“c@ÈAŠÖ@”Ž”Vi•ÒWjDŽ™“ª‰º~“x‚Ì•]‰¿‚ÆççŽq‹•Øp ˆÀ‘SEŠmŽÀ‚È‹zˆøEççŽq•ª•Ø‚Ì‚½‚ß‚É ˜•¶DƒƒWƒJƒ‹ƒrƒ…[ŽÐ@2015”N4ŒŽ1“ú
  5. ‘è ‰p–¾ , ’|“c È , ’r“c ’q–¾ , –Ø‘º ³ , H“¡ ”üŽ÷ , ‹v•Û —²•F , âV“¡ Ž  , ²“¡ ¹Ži , ™‰Y ^‹| , ` —˜”V , “¡X Œh–ç , …ã ®“TDŽüŽYŠúˆÏˆõ‰ï(•½¬27”N“xê–åˆÏˆõ‰ï•ñ)D“ú–{ŽY‰È•wl‰È›{˜ð趎 67(6), 1517-1566, 2015-06-01
  6. Œ¤‹†‘ã•\ŽÒ@“¡Œ´@Œbˆê@Œ¤‹†‹¦—͎ҁ@’|“c@ÈD•½¬27”N“xŒú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹àˆã—ËZpŽÀ—p‰»‘‡Œ¤‹†Ž–‹Æ
  7. is—‘‘ƒŠàE—‘ŠÇŠàE• –ŒŠà‚ɑ΂·‚é• o“à‰»Šw—Ö@Šm—§‚Ì‚½‚ß‚ÌŒ¤‹†@•½¬26”N“x@‘Š‡Œ¤‹†•ñ‘D•½¬27”N3ŒŽ
  8. ƒZƒ“ƒ^[’·@¬Š}Œ´‰xŽq@Œ¤‹†ƒvƒƒWƒFƒNƒgƒƒ“ƒo[@ŒE@–ƒ—R”üA“c“ˆ@“ցA–ko^—A’|“c@ÈA’r“c˜a”ŽAˆäã@‘A‘¼D•½¬26”N“x‡“V“°‘åŠw‘åŠw‰@ƒXƒ|[ƒcŒ’N‰ÈŠwŒ¤‹†‰È—«ƒXƒ|[ƒcŒ¤‹†ƒZƒ“ƒ^[‹I—v
  9. –ko^—D—«ƒAƒXƒŠ[ƒgŠO—ˆ@ŠJ‚©‚ꂽƒ`[ƒ€ˆã—Âð–ÚŽw‚µ‚āD—«ƒXƒ|[ƒcƒIƒ“ƒ‰ƒCƒ“Women in Sport@2015
  10. –ko^—D—«ƒAƒXƒŠ[ƒgŠO—ˆ‚̈Ӌ`‚ƃƒfƒBƒJƒ‹ƒTƒ|[ƒg
  11. \‹£‹ZƒpƒtƒH[ƒ}ƒ“ƒXŒüã‚Ì‚½‚ß‚ÉŽ„’B‚ª‚Å‚«‚鎖\Dˆã—ØAŒg‚ð‹¤‚Él‚¦‚é‰ï. (“Œ‹ž)
  12. –ko^—A‘å{‰êõDŽèp”‚Å‚í‚©‚é‚¢‚¢•a‰@ ‘S‘’n•û•Êƒ‰ƒ“ƒLƒ“ƒO 2016@-—«‚̗ǐ«Ž¾Š³-D’©“úV•·o”Å 2015/9/28
  13. –ko^—D2016”N“x”Ł@‘–¯‚Ì‚½‚ß‚Ì–¼ˆãƒ‰ƒ“ƒLƒ“ƒOD÷‚̉ԏo”Å 2015/11/11
  14. –ko^—Dƒpƒ‰ƒŒƒ‹–@‚ōs‚¤• o‹¾‰ºŽèp‚ł̑̍o“à–D‡EŒ‹ãFD“ú–{“àŽ‹‹¾ŠO‰ÈŠw‰ïŽåÃ@–D‡uK‰ï, 2015 “Œ‹ž
  15. ‘¾“c„ŽuD—‘‘ƒŠà‚Ɖ»Šw—Ö@@--2nd-line‰»Šw—Ö@‚ÌŽ¡—ÑI‘ð--Dƒ„ƒ“ƒZƒ“ƒtƒ@[ƒ}u‰‰‰ï@(“Œ‹ž 2015/8/18)
  16. ‘¾“c„ŽuD—‘‘ƒ‚ª‚ñ‚Ɖ»Šw—Ö@@-2nd-line‰»Šw—Ö@‚Ì‘I‘ð‚ƃxƒoƒVƒcƒ}ƒu‚Ì“±“ü-D’†ŠO»–òu‰‰‰ï@(“Œ‹ž 2015/11/12)
  17. –Ø‘º”üˆ¨DŽq‹{èò‚ª‚ñ@`ŒŸf‚©‚玡—Á`D•iì—ŽqŠw‰@‚Z@(“Œ‹ž 2015/2/14)
  18. –q–ì^‘¾˜YD—§‰ï‚¢oŽYA‚»‚Ì‘O‚É‚Å‚«‚邱‚Æ‚Á‚āHD‚¨ˆãŽÒ‚³‚ñ‚ª‚‚­‚Á‚½”DPEoŽY‚̏î•ñƒTƒCƒg Baby+ https://akasugu.fcart.jp/babyplus/articles/7fgj6/
  19. –q–ì^‘¾˜Y@’|“c ÈDŽ©•ª‚̃ŠƒXƒN‚ð’m‚Á‚ÄŽY‰@‚ð‘I‚Ú‚¤DHUMAN + —‚Æ’j‚̂̃fƒBƒNƒVƒ‡ƒiƒŠ[@http://humanplus.jp
  20. –q–ì^‘¾˜YD‚Ó‚½‚²ƒNƒ‰ƒuDBenesse ‚½‚Ü‚²ƒNƒ‰ƒu@(˜AÚ)
  21. •“cŒbŽiDƒf[ƒ^‚©‚çl‚¦‚é‚ ‚È‚½‚Ì”DP—́Dƒxƒr‘Ò‚¿ƒJƒbƒvƒ‹‚Ì‚½‚ß‚ÌŽq•óƒZƒ~ƒi[ (“Œ‹ž 2015/7/12)
  22. •“cŒbŽiDŽq‹{“à–ŒÇ‚̐f’f‚ÆŽ¡—ÁD“ú–{V–òŽÐ“àŒ¤C‰ï (“Œ‹ž 2015/2/24)
  23. Ž•½@’•¶A“¡–ì@ˆê¬A–Ø‘º@”üˆ¨A@‘¾“c@„ŽuAŽ›”ö@‘׋vA’|“c@ÈD“–‰@‚É‚¨‚¯‚éÄ”­Eis—‘‘ƒŠà‚ɑ΂·‚é ƒxƒoƒVƒYƒ}ƒuŽg—pŒoŒ±DTokyo ovarian cancer summit@(“Œ‹ž 2015/6/19)
  24. ²–ì–õŽqA’r–{—TŽqAˆäŽR”üˆ¨A’|“c@ÈD–½‚ðŽx‚¦‚é♥–¢—ˆƒrƒWƒ‡ƒ“À’k‰ï@‚Ç‚¤‚µ‚Ä‚¢‚Ü‚·‚©HŽY•wl‰Èˆã‚́uŽdŽ–v‚ƁuŽqˆç‚āvDƒAƒlƒeƒBƒX2015‰Ä†
  25. ’|“c@ƒA’|“c@ÈD”D•wŒ’f‚͎󂯂Ȃ¢‚Æ‚¢‚¯‚È‚¢‚́H HUMAN+ Baby{@‚¨ˆãŽÒ‚³‚ñ‚ª‚‚­‚Á‚½”DPEoŽY‚Ì–{D“ú–{ŽY‰È•wl‰ÈŠw‰ï@ŠÄC@2015”N9ŒŽ30“ú

Copyright © 2005 JUNTENDO All Rights Reserved.